Author: webdev

  • Ispire Technology Inc. Schedules Fiscal Third Quarter 2026 Earnings Conference Call

    Ispire Technology Inc. Schedules Fiscal Third Quarter 2026 Earnings Conference Call

    LOS ANGELES, May 1, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Thursday, May 7, 2026, to discuss the Company’s financial results for its fiscal third quarter ended March 31, 2026.

    To listen to the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the “Ispire Technology Call.”

    • Date: Thursday, May 7, 2026

    • Time: 8:00 am ET

    • Dial-In Numbers: United States 844-826-3033 or International + 1-412-317-5185

    This conference call will be webcast live and can be accessed by all interested parties at  https://viavid.webcasts.com/starthere.jsp?ei=1761477&tp_key=3958311007

    Please access the link at least fifteen minutes prior to the start of the call to register, download, and install any necessary audio software.

    A playback will be available until 11:59 pm ET on Friday, May 21, 2026. To listen, please dial 1-844-512-2921 or 1-412-317-6671. Use the passcode 10208863 to access the replay.

    About Ispire Technology Inc.
    Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on InstagramLinkedInTwitter and YouTube.

    Investor Contacts:

    Brett Maas
    Hayden IR
    (646) 536-7331
    [email protected]

    James Carbonara
    Hayden IR
    (646)-755-7412
    [email protected]

    SOURCE Ispire Technology Inc.


    Read original release

  • Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset Value

    Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset Value

    • FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirement

    • FDA guidance unlocks an estimated $50 billion total addressable market, allowing companies to lawfully transition the 70% illicit flavored vape market into a compliant ecosystem

    • Ispire’s 40%-owned IKE Tech joint venture is positioned to generate $5 million to $20 million in annual recurring SaaS revenue per customer in the US

    • Based on conservative SaaS metrics, even a limited number of customers could potentially value the IKE joint venture in the hundreds of millions, dramatically increasing Ispire’s book value

    • Ispire-backed IKE Tech was first to file component PMTA for continuous, blockchain-enabled age-gating technology

    LOS ANGELES, March 16, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, today highlighted the massive economic value and multi-billion-dollar market opportunity created for its shareholders by the U.S. Food and Drug Administration’s (FDA) newly issued draft guidance outlining evidentiary expectations for Premarket Tobacco Product Applications (PMTAs) for flavored electronic nicotine delivery systems (ENDS).

    The FDA’s guidance effectively unlocks a $50 billion total addressable market by providing a lawful pathway for flavored vapes, which currently consist largely of illicit products. Ispire’s 40%-owned joint venture, IKE Tech LLC (“IKE Tech” or “IKE”), is uniquely positioned to capture this market. IKE’s recurring SaaS revenue model is expected to generate $5 million to $20 million annually per customer. Management believes that securing even a limited number of customers could value the IKE joint venture in the hundreds of millions, creating a highly valuable asset on Ispire’s balance sheet.

    The guidance marks the first time the FDA has formally outlined a framework for evaluating flavored ENDS products, recognizing that device-level access technologies — or Device Access Restrictions (DAR) — may factor into whether a product meets the “appropriate for the protection of public health” (APPH) standard for PMTA authorization.

    The draft guidance highlights DAR technologies such as biometric authentication, geofencing, and continuous age verification as potential safeguards designed to prevent underage use of ENDS devices. FDA also emphasizes that traditional safeguards such as local age restrictions and point-of-sale verification that do not directly prevent youth use may not, when employed alone, sufficiently reduce youth use.

    “We believe this guidance represents a major step toward a technology-enabled regulatory framework for the vapor category,” said Michael Wang, Co-Chief Executive Officer of Ispire. “FDA’s recognition of Device Access Restrictions validates our long-held position that continuous, device-level age verification can protect youth while preserving adult choice.”

    Ispire has long advocated for technology-driven youth prevention solutions. Through IKE, a joint venture that includes Ispire as a founding partner, the Company has supported the development of advanced identity and authentication systems designed to control device access directly at the point of use, rather than solely at the point of sale.

    In 2025, IKE Tech submitted the first-ever component PMTA for a standalone, interoperable age-verification technology designed for integration across ENDS devices. The platform combines Bluetooth Low Energy (BLE) chips, biometric authentication, and blockchain-secured identity verification to ensure that only verified adult users can activate a device. In a multi-center Human Factors Validation Study submitted with the PMTA, the IKE age-gating technology achieved:

    • 100% effectiveness in preventing device activation by underage users
    • 100% accuracy in demographic verification
    • User error rates below 1%, underscoring ease of use for adults
    • 91% user satisfaction with app simplicity and functionality

    In addition to age verification, the IKE technology platform can also support product authentication and anti-counterfeiting capabilities, helping manufacturers and regulators identify illicit or counterfeit devices that bypass regulatory safeguards, evade taxes, and undermine consumer safety.

    Economic Opportunity and Market Impact
    The FDA’s draft guidance may immediately unlock access to a multi-billion-dollar segment of the U.S. vapor market. With flavored products representing a substantial portion of consumer demand, the agency’s recognition of DAR creates a potential pathway for compliant manufacturers to compete in segments previously dominated by illicit trade.

    Industry estimates suggest that approximately 70% of the current U.S. vape market consists of illicit or unauthorized products. Data suggests that the total U.S. vapor market is currently around $50 billion annually, when accounting for hard-to-track illicit and unauthorized products. IKE’s technological solutions will allow companies to address this massive total market.

    Over recent months, IKE Tech is actively working with large tobacco companies, leading independent brands, and several of the largest e-cigarette manufacturers to evaluate integration of its technology into flavored PMTA submissions, while also receiving strong inbound interest from manufacturers seeking to bring compliant flavored ENDS products to the U.S. market.

    Following the FDA’s guidance, Ispire believes this framework could also influence global regulatory policy, with several major markets potentially moving toward mandating device-level age verification for ENDS products.

    IKE’s business model is structured as a recurring compliance technology platform, generating SaaS revenue from manufacturers integrating the system into their devices. Each customer using the technology is expected to generate approximately $5 million – $20 million in annual recurring SaaS revenue, alongside recurring per-device hardware sales or firmware licensing fees. Even a limited number of authorized flavored ENDS products incorporating IKE’s technology could create significant enterprise value for the platform. 

    About IKE Tech LLC
    IKE Tech LLC is a joint venture comprised of Ispire Technology Inc., Touch Point Worldwide Inc. d/b/a Berify, and Chemular Inc. Founded in 2024, IKE Tech is building the identity layer for the physical world. With patented technologies spanning blockchain authentication, secure BLE communication, and AI-enhanced access control, IKE powers secure, user-centric device interactions across regulated and high-risk sectors.

    IKE’s System-on-a-Chip allows manufacturers to embed customizable, interoperable access controls into vapor devices — ensuring authorized adult use and preventing youth access through real-time mobile and biometric authentication. Visit www.iketech.com.

    About Ispire Technology Inc.
    Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

    Forward Looking Statements
    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

    IR Contact:
    Phil Carlson
    +1-212-896-1233
    [email protected]

    PR Contact:
    Ellen Mellody
    +1-570-209-2947
    [email protected]

    SOURCE Ispire Technology Inc.


    Read original release

  • Ispire Highlights Economic Impact of New FDA Guidance on Flavored ENDS Unlocking a $50 Billion Market and Driving Significant Potential Asset Value

    FDA establishes first-ever framework for flavored ENDS, recognizing device level age verification as a regulatory requirement

    FDA guidance unlocks an estimated $50 billion total addressable market, allowing companies to lawfully transition the 70% illicit flavored vape market into a compliant ecosystem

    Ispire’s 40%-owned IKE Tech joint venture is positioned to generate $5 million to $20 million in annual recurring SaaS revenue per customer in the US

    Based on conservative SaaS metrics, even a limited number of customers could potentially value the IKE joint venture in the hundreds of millions, dramatically increasing Ispire’s book value

    Ispire-backed IKE Tech was first to file component PMTA for continuous, blockchain-enabled age-gating technology
    LOS ANGELES, March 16, 2026 /PRNewswire/ — Ispire Technology Inc. (“Ispire” or the “Company”) (NASDAQ: ISPR), a trailblazer in vaping technology and precision dosing, today highlighted the massive economic value and multi-billion-dollar market opportunity created for its shareholders by the U.S. Food and Drug Administration’s (FDA) newly issued draft guidance outlining evidentiary expectations for Premarket Tobacco Product Applications (PMTAs) for flavored electronic nicotine delivery systems (ENDS).

    The FDA’s guidance effectively unlocks a $50 billion total addressable market by providing a lawful pathway for flavored vapes, which currently consist largely of illicit products. Ispire’s 40%-owned joint venture, IKE Tech LLC (“IKE Tech” or “IKE”), is uniquely positioned to capture this market. IKE’s recurring SaaS revenue model is expected to generate $5 million to $20 million annually per customer. Management believes that securing even a limited number of customers could value the IKE joint venture in the hundreds of millions, creating a highly valuable asset on Ispire’s balance sheet.

    The guidance marks the first time the FDA has formally outlined a framework for evaluating flavored ENDS products, recognizing that device-level access technologies — or Device Access Restrictions (DAR) — may factor into whether a product meets the “appropriate for the protection of public health” (APPH) standard for PMTA authorization.

    The draft guidance highlights DAR technologies such as biometric authentication, geofencing, and continuous age verification as potential safeguards designed to prevent underage use of ENDS devices. FDA also emphasizes that traditional safeguards such as local age restrictions and point-of-sale verification that do not directly prevent youth use may not, when employed alone, sufficiently reduce youth use.

    “We believe this guidance represents a major step toward a technology-enabled regulatory framework for the vapor category,” said Michael Wang, Co-Chief Executive Officer of Ispire. “FDA’s recognition of Device Access Restrictions validates our long-held position that continuous, device-level age verification can protect youth while preserving adult choice.”

    Ispire has long advocated for technology-driven youth prevention solutions. Through IKE, a joint venture that includes Ispire as a founding partner, the Company has supported the development of advanced identity and authentication systems designed to control device access directly at the point of use, rather than solely at the point of sale.

    In 2025, IKE Tech submitted the first-ever component PMTA for a standalone, interoperable age-verification technology designed for integration across ENDS devices. The platform combines Bluetooth Low Energy (BLE) chips, biometric authentication, and blockchain-secured identity verification to ensure that only verified adult users can activate a device. In a multi-center Human Factors Validation Study submitted with the PMTA, the IKE age-gating technology achieved:

    • 100% effectiveness in preventing device activation by underage users
    • 100% accuracy in demographic verification
    • User error rates below 1%, underscoring ease of use for adults
    • 91% user satisfaction with app simplicity and functionality
    • In addition to age verification, the IKE technology platform can also support product authentication and anti-counterfeiting capabilities, helping manufacturers and regulators identify illicit or counterfeit devices that bypass regulatory safeguards, evade taxes, and undermine consumer safety.

    Economic Opportunity and Market Impact

    The FDA’s draft guidance may immediately unlock access to a multi-billion-dollar segment of the U.S. vapor market. With flavored products representing a substantial portion of consumer demand, the agency’s recognition of DAR creates a potential pathway for compliant manufacturers to compete in segments previously dominated by illicit trade.

    Industry estimates suggest that approximately 70% of the current U.S. vape market consists of illicit or unauthorized products. Data suggests that the total U.S. vapor market is currently around $50 billion annually, when accounting for hard-to-track illicit and unauthorized products. IKE’s technological solutions will allow companies to address this massive total market.

    Over recent months, IKE Tech is actively working with large tobacco companies, leading independent brands, and several of the largest e-cigarette manufacturers to evaluate integration of its technology into flavored PMTA submissions, while also receiving strong inbound interest from manufacturers seeking to bring compliant flavored ENDS products to the U.S. market.

    Following the FDA’s guidance, Ispire believes this framework could also influence global regulatory policy, with several major markets potentially moving toward mandating device-level age verification for ENDS products.

    IKE’s business model is structured as a recurring compliance technology platform, generating SaaS revenue from manufacturers integrating the system into their devices. Each customer using the technology is expected to generate approximately $5 million – $20 million in annual recurring SaaS revenue, alongside recurring per-device hardware sales or firmware licensing fees. Even a limited number of authorized flavored ENDS products incorporating IKE’s technology could create significant enterprise value for the platform.

    About IKE Tech LLC

    IKE Tech LLC is a joint venture comprised of Ispire Technology Inc., Touch Point Worldwide Inc. d/b/a Berify, and Chemular Inc. Founded in 2024, IKE Tech is building the identity layer for the physical world. With patented technologies spanning blockchain authentication, secure BLE communication, and AI-enhanced access control, IKE powers secure, user-centric device interactions across regulated and high-risk sectors.

    IKE’s System-on-a-Chip allows manufacturers to embed customizable, interoperable access controls into vapor devices — ensuring authorized adult use and preventing youth access through real-time mobile and biometric authentication. Visit www.iketech.com.

    About Ispire Technology Inc.

    Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 400 patents worldwide. Ispire’s branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company’s cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: whether the Company may be successful in re-entering the U.S. ENDS market; the approval or rejection of any PMTA submitted by the Company; whether the Company will be successful in its plans to further expand into the African market; whether the Company’s joint venture with Touch Point Worldwide Inc. d/b/a/ Berify and Chemular Inc. (the “Joint Venture”) may be successful in achieving its goals as currently contemplated, with different terms, or at all; the Joint Venture’s ability to innovate in the e-cigarette technology space or develop age gating or age verification technologies for nicotine vaping devices; the Company’s ability to collect its accounts receivable in a timely manner; the Company’s business strategies; the ability of the Company to market to the Ispire ONE™; Ispire ONE™’s success in meeting its goals; the ability of its customers to derive the anticipated benefits of the Ispire ONE™ and the success of its products on the markets; the Ispire ONE™ proving to be safe; and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Cautionary Note on Forward-Looking Statements” and the additional risk described in Ispire’s Annual Report on Form 10-K for the year ended June 30, 2025 and any subsequent filings which Ispire makes with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by applicable law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

    IR Contact:
    Phil Carlson
    +1-212-896-1233
    ispire@kcsa.com

    PR Contact:
    Ellen Mellody
    +1-570-209-2947
    ispire@kcsa.com

    SOURCE Ispire Technology Inc.

     

  • Ispire Technology Inc. 將參與第 38 屆年度 ROTH Conference

    Ispire Technology Inc. 將參與第 38 屆年度 ROTH Conference

    洛杉磯2026年3月11日 /美通社/ — Ispire Technology Inc. (NASDAQ: ISPR)(「Ispire」、「公司」、「我們」或「我方」),一家專注於電子霧化技術及精準劑量技術的創新企業,今日宣布 Ispire 管理團隊將參與於 2026 年 3 月 22 日至 24 日在加州達納波因特舉行的第 38 屆年度 ROTH Conference。

    第 38 屆年度 ROTH Conference
    日期:2026 年 3 月 22 日至 24 日
    地點:加州達納波因特
    爐邊對談詳情:2026 年 3 月 23 日(星期一)太平洋時間上午 8:00, 於 Blue-Consumer-Salon 2

    如欲安排與本公司管理團隊進行單獨會面,請聯絡您在 ROTH 的代表,或電郵 [email protected] 聯絡 KCSA Strategic Communications。

    關於 Ispire Technology Inc.
    Ispire 從事品牌電子煙及大麻霧化產品的研發、設計、商業化、銷售、市場推廣及分銷。 本公司的營運附屬公司在全球已取得或申請超過 200 項專利。 Ispire 的煙草產品以 Aspire 品牌名銷售,並主要透過其環球分銷網絡於全球各地銷售(美國、中華人民共和國及俄羅斯除外)。 本公司的大麻產品則以 Ispire 品牌名銷售,主要以原廠委託設計代工 (ODM) 形式為其他大麻霧化公司提供產品。 Ispire 的大麻霧化硬件目前僅在美國銷售,最近並已於加拿大及歐洲展開市場推廣活動。 如欲了解更多資訊,請瀏覽 www.ispiretechnology.com,或到 InstagramLinkedInTwitter 及 YouTube 關注 Ispire。 在該公司網站、任何其他網站或任何社交媒體上所載或可透過其存取的任何資訊,均不屬於本新聞稿的一部分。

    如需更多資訊,請聯絡:

    投資者關係聯絡人:
    KCSA Strategic Communications
    投資者關係部
    Phil Carlson
    212-896-1233
    [email protected]

    公共關係聯絡人:
    Ellen Mellody
    570-209-2947
    [email protected]

    SOURCE Ispire Technology Inc.


    Read original release

  • Ispire Technology Inc.、第38回年次ROTHカンファレンスに参加

    Ispire Technology Inc.、第38回年次ROTHカンファレンスに参加

    ロサンゼルス, 2026年3月11日 /PRNewswire/ — Ispire Technology Inc. (NASDAQ:ISPR)(「Ispire」、「当社」、または「当社の」)は、Ispireの経営陣が2026年3月22日から24日までカリフォルニア州デイナポイントで開催される第38回年次ROTHカンファレンスに参加することを発表しました。

    第38回年次ROTHカンファレンス
    日時:2026年3月22~24日
    場所:カリフォルニア州デイナポイント
    ファイアサイドチャットの詳細2026年3月23日(月)午前8時(太平洋時間)、ブルー・コンシューマー・サロン2にて開催

    当社の経営陣との個別面談をご希望の方は、ROTHの担当者までご連絡いただくか、 KCSA Strategic Communications[email protected] までEメールをお送りください。

     Ispire Technology Inc.について
    Ispire は、電子タバコおよび大麻用ベーピング製品の研究開発、設計、商品化、販売、マーケティング、ならびに流通に従事しています。当社の事業子会社は、世界中で取得または出願された200件を超える特許を所有またはライセンスしています。Ispire のタバコ製品は「Aspire」の名称で販売されており、米国・中華人民共和国・ロシアを除く世界各国で、主にグローバルな流通ネットワークを通じて提供されています。当社の大麻製品は、Ispire のブランド名で主に original design manufacturer(ODM)ベースで他の大麻蒸気会社に販売されています。Ispireは、大麻を吸引するハードウェアを米国でのみ販売しており、このほどカナダと欧州でマーケティング活動を開始しています。詳細は www.ispiretechnology.comをご覧いただくか、Instagram、 LinkedInTwitter、 、YouTubeでIspireをフォローしてください。当社のウェブサイト、その他のウェブサイトまたはソーシャルメディアに含まれる、またはそれらを通じてアクセスできるいかなる情報も、本プレスリリースの一部ではありません。

    詳細については、以下にお問い合わせください。

    IRに関するお問い合わせ先:
    インベスター・リレーションズ
    KCSA Strategic Communications
    Phil Carlson
    212-896-1233
    [email protected]

    PRに関するお問い合わせ先:
    Ellen Mellody
    570-209-2947
    [email protected]

    ロゴ – https://mma.prnewswire.com/media/2771569/Ispire_Technology_Logo.jpg

    SOURCE Ispire Technology Inc.


    Read original release

  • Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

    Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

    LOS ANGELES, March 11, 2026 /PRNewswire/ — Ispire Technology Inc. (NASDAQ: ISPR) (“Ispire,” the “Company,” “we,” “us,” or “our”), an innovator in vaping technology and precision dosing, today announced that Ispire’s management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026.

    38th Annual ROTH Conference
    Date: March 22-24, 2026
    Location: Dana Point, California
    Fireside Chat Details: Monday, March 23, 2026, at 8:00 a.m. PT in Blue-Consumer-Salon 2

    To schedule a one-on-one meeting with the Company’s management team, please contact your representative at ROTH, or email KCSA Strategic Communications at [email protected].

    About Ispire Technology Inc.
    Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 200 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on InstagramLinkedIn, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company’s website, any other website or any social media, is not a part of this press release.

    For more information, kindly contact:

    IR Contacts:
    Investor Relations
    KCSA Strategic Communications
    Phil Carlson
    212-896-1233
    [email protected]

    PR Contact:
    Ellen Mellody
    570-209-2947
    [email protected]

    SOURCE Ispire Technology Inc.


    Read original release

  • Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

    Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

    LOS ANGELES, March 11, 2026 /PRNewswire/ — Ispire Technology Inc. (NASDAQ: ISPR) (“Ispire,” the “Company,” “we,” “us,” or “our”), an innovator in vaping technology and precision dosing, today announced that Ispire’s management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026.

    38th Annual ROTH Conference
    Date: March 22-24, 2026
    Location: Dana Point, California
    Fireside Chat Details: Monday, March 23, 2026, at 8:00 a.m. PT in Blue-Consumer-Salon 2

    To schedule a one-on-one meeting with the Company’s management team, please contact your representative at ROTH, or email KCSA Strategic Communications at [email protected].

    About Ispire Technology Inc.
    Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 200 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on InstagramLinkedIn, Twitter and YouTube. Any information contained on, or that can be accessed through, the Company’s website, any other website or any social media, is not a part of this press release.

    For more information, kindly contact:

    IR Contacts:
    Investor Relations
    KCSA Strategic Communications
    Phil Carlson
    212-896-1233
    [email protected]

    PR Contact:
    Ellen Mellody
    570-209-2947
    [email protected]

    SOURCE Ispire Technology Inc.


    Read original release

  • Ispire Technology Inc. to Participate in the 38th Annual ROTH Conference

    Los Angeles, March 11, 2026 – Ispire Technology Inc. (NASDAQ: ISPR) (“Ispire,” the “Company,” “we,” “us,” or “our”), an innovator in vaping technology and precision dosing, today announced that Ispire’s management team will participate in the 38th Annual ROTH Conference taking place in Dana Point, California from March 22-24, 2026.

    38th Annual ROTH Conference
    Date: March 22-24, 2026
    Location: Dana Point, California
    Fireside Chat Details: Monday, March 23, 2026, at 8:00 a.m. PT in Blue-Consumer-Salon 2

    To schedule a one-on-one meeting with the Company’s management team, please contact your representative at ROTH, or email KCSA Strategic Communications at Ispire@KCSA.com.

    About Ispire Technology Inc.
    Ispire is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The Company’s operating subsidiaries own or license more than 200 patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the U.S., People’s Republic of China and Russia) primarily through its global distribution network. The Company’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware only in the U.S., and it recently commenced its marketing activities in Canada and Europe. For more information, visit www.ispiretechnology.com or follow Ispire on InstagramLinkedInTwitter and YouTube. Any information contained on, or that can be accessed through, the Company’s website, any other website or any social media, is not a part of this press release.

    For more information, kindly contact:

    IR Contacts:
    Investor Relations
    KCSA Strategic Communications
    Phil Carlson
    212-896-1233
    ispire@kcsa.com

    PR Contact:
    Ellen Mellody
    570-209-2947
    EMellody@kcsa.com

  • Ispire Technology Inc. 發佈 2026 財政年度第二季財務業績

    Ispire Technology Inc. 發佈 2026 財政年度第二季財務業績

    不斷加強收款工作令應收帳款淨額自 2025 年 6 月 30 日起減少 19%,而

    現金
    截至 2025 年 12 月 31 日的金額為 1,760 萬美元 

    洛杉磯2026年2月8日 /美通社/ — Ispire Technology Inc. (NASDAQ: ISPR)(「Ispire」、「公司」、「我們」或「我方」)是一家在電子煙技術和精準劑量方面具有創新精神的公司,今天公佈其截至 2025 年 12 月 31 日的 2026 財政年度第二季財務業績。

    2026 財政年度第二季財務業績

    • 收益為 2,030 萬美元,而 2025 財政年度第二季為 4,180 萬美元。
    • 毛利為 350 萬美元,而 2025 財政年度第二季為 770 萬美元。
    • 毛利率為 17.1%,而 2025 財政年度第二季為 18.5%。
    • 總營運開支為 1,030 萬美元,而 2025 財政年度第二季為 1,510 萬美元。
    • 淨虧損為 660 萬美元,而 2025 財政年度第二季淨虧損為 800 萬美元。

    Ispire 聯席行政總裁 Michael Wang 評論道:「在為期一年的成本削減及客戶質素合理化工作中,本季度對 Ispire 而言是一個轉捩點。我們相信未來幾季將能提升營業額、穩定現金流和改善利潤。 我們有信心為未來的成功奠定堅實的基礎。 在 2026 財政年度第二季,我們繼續專注於優先實現高質素收益,並加強我們嚴謹精密、深思熟慮的可持續增長方式。 這在我們努力減少應收帳款淨額方面尤為明顯,並且一直取得顯著成效。 在財政年度第二季,我們的應收帳款淨額減少了19.5% 至 3,790 萬美元,而 2025 財政年度結束的淨應收帳款為 4,700 萬美元。

    Wang 先生總結:「我們繼續在業務的核心領域奠定重要基礎,包括提升我們在馬來西亞的生產能力,為 2026 財政年度提高產量做好準備。 我們專有的 G-Mesh 科技發展氣勢持續強勁,多家大型和中型尼古丁生產商正在參與討論,評估其在下一代電子煙裝置中的應用。我們也正努力尋求潛在的授權和合作機會。 此外,我們的 IKE Tech 合資企業正在全球穩步發展,與歐洲、東南亞和中東的監管機構合作,支持更廣泛地採用年齡限制技術,使其成為更安全的行業標準。  在美國,雖然大多數成年消費者想吸調味電子煙,但幾乎所有調味電子煙都未能獲得美國食品藥物管理局 (FDA) 的授權,而且都是透過非法渠道銷售。  我們歡迎美國聯邦政府加強對非法電子煙貿易的執法力度,但我們認為,唯有將這種執法與建立一個強大、合法、經 FDA 授權的調味電子煙產品市場結合,才能真正奏效。 Ispire 與 IKE 是建立合法、經批准產品市場的重要參與者,利用其技術防止未成年人獲取產品,確保產品正宗,並提供解決方案來保護裝置免受濫用。 我們看到美國 FDA 對調味電子煙產品和年齡限制的既定立場,會為我們帶來宏觀的利好因素。 自 2025 年 10 月起,FDA 的立場明確,若想調味產品獲得批准,就必須採用年齡限制技術。 Ispire 透過與 IKE 的合資企業,擁有該領域領先在前而阻礙極小的技術,我們期待在適當時候抓住這機會。」 Ispire, through its IKE joint venture, has one of the leading and most low friction technologies in this space, and we look forward to capitalizing on this opportunity in due time”, Mr. Wang concluded.

    Ispire 財務總監 Jay Yu 表示:「2026 財政年度第二季業績反映我們在加強公司財務基礎方面不斷取得進展。 嚴格的成本控制推動營運費用逐年遞減,財政年度第二季的營運費用由 1,510 萬美元降至 1,030 萬美元,突顯我們提高效率措施的影響。 截至 2025 年 12 月 31 日,我們的淨應收帳款亦下降至 3,790 萬美元,而截至 2025 年 6 月 30 日為 4,700 萬美元,這反映我們不斷專注於更高質素的客戶。 這些舉措將使公司財務更加靈活,並支持公司在長期內繼續創造價值。」

    截至 2025 年 12 月 31 日財政年度第二季財務表現

    Ispire 公佈截至 2025 年 12 月 31 日的財政年度第二季收益為 2,030 萬美元,而去年同期收益為 4,180 萬美元。 收益下降是由於策略重心從低級大麻客戶轉移到高級大麻客戶,導致整體產品銷售下降。 

    2026 財政年度第二季毛利為 350 萬美元,而上年同期為 770 萬美元。 毛利率為 17.1%,而 2025 財政年度第二季為 18.5%。 毛利率下降主要是由於產品組合發生變化,截至 2025 年 12 月 31 日的三個月內,高利潤率產品的銷售量減少。

    2026 財政年度第二季總營運開支為 1,030 萬美元,而去年同期為 1,510 萬美元。

    2026 財政年度第二季淨虧損 660 萬美元,即每股虧損 0.12 美元,而 2025 財政年度第二季淨虧損 800 萬美元,即每股虧損 0.14 美元。

    截至 2025 年 12 月 31 日,Ispire 持有現金 1,760 萬美元,營運資本 350 萬美元。

    電話會議

    公司將於 2026 年 2 月 6 日(星期五)上午 8:00(美國東部時間)舉行電話會議,討論業績,隨後進行問答環節。

    如欲收聽電話會議,請使用以下資料致電。 致電時,請依照指示要求加入「Ispire Technology 電話會議」。

    • 日期:2026 年 2 月 6 日(星期五)
    • 時間:上午 8:00(美國東部時間)
    • 電話號碼:877-451-6152(美國)或 +1 201-389-0879(國際)

    本電話會議將安排網絡直播,如有興趣即可參加:https://viavid.webcasts.com/starthere.jsp?ei=1749224&tp_key=1ec45fe266

    請在電話會議開始前至少 15 分鐘存取連結以便註冊、下載和安裝任何必要的音訊軟件。

    重播服務將於 2026 年 2 月 20 日(星期五)晚上 11:59(美國東部時間)前結束。 如要收聽,請致電:1-844-512-2921 或 1-412-317-6671。 使用密碼 13758138 存取重播內容。

    關於 Ispire Technology Inc.
    Ispire 從事品牌電子煙和大麻霧化產品的研發、設計、商業化、銷售、市場推廣和分銷。 公司旗下營運子公司在全球擁有或授權使用超過 400 項專利。 Ispire 的品牌電子煙產品以 Aspire 的名義銷售,主要透過其全球分銷網絡在全球銷售(美國、中華人民共和國和俄羅斯除外)。 公司也與全球電子煙品牌和零售商建立原廠委託設計代工 (ODM) 合作關係。 公司的大麻產品主要以 ODM 模式向其他大麻電子煙公司銷售,並以 Ispire 品牌銷售。 Ispire 在美國、歐洲和南非銷售其大麻電子煙硬件,最近開始在加拿大和拉丁美洲開展市場推廣活動和客戶互動。 如欲了解更多資訊,請瀏覽 www.ispiretechnology.com 或在 InstagramLinkedInTwitter 和 YouTube 關注 Ispire。

    前瞻性陳述
    本新聞稿包含《1933 年證券法》(經修訂)第 27A 條、《1934 年證券交易法》(經修訂)第 21E 條以及《1995 年私人證券訴訟改革法》(經修訂)所指的前瞻性陳述,旨在受到上述條款所建立的安全港條款的保護。 前瞻性陳述是基於某些假設,描述公司未來的計劃、策略和預期,通常可以透過使用「相信」、「預期」、「也許」、「將」、「應該」、「會」、「可以」、「尋求」、「打算」、「計劃」、「目標」、「項目」、「估計」、「預計」、「策略」、「未來」、「可能」或其他類似術語,儘管並非所有前瞻性陳述都包含這些識別詞語。 本新聞稿除歷史事實陳述外,有關公司策略、前景、財務狀況、營運、成本、計劃和目標的所有陳述均為前瞻性陳述。 可能導致公司實際業績和財務狀況與前瞻性陳述中所示業績和財務狀況有重大差異的重要因素。 此類前瞻性陳述包括但不限於風險和不確定性,包括以下方面:公司能否成功重返美國電子尼古丁傳送系統市場;公司提交的任何煙草產品上市前申請 (PMTA) 是否獲得批准或拒絕;公司能否成功落實進一步拓展非洲市場的計劃;公司與 Touch Point Worldwide Inc.(以 Berify 名義開展業務)和 Chemular Inc.(下稱「合資企業」)的合資企業能否按照目前設想的方式、以不同的條款或根本無法實現目標;合資企業在電子煙技術領域進行創新或開發尼古丁電子煙裝置的年齡限制或年齡驗證技術的能力;公司及時收回應收帳款的能力;公司的商業策略;公司向 Ispire ONE™ 進行市場推廣的能力;Ispire ONE™ 實現其目標的成功情況;客戶能否獲得 Ispire ONE™ 的預期收益以及其產品在市場是否成功;Ispire ONE™ 被證明是安全;以及「風險因素」、「管理階層對財務狀況和經營業績的討論與分析」、「關於前瞻性陳述的警示性說明」中所述的風險和不確定性,以及 Ispire 截至 2025 年 6 月 30 日止年度的 10-K 表格年度報告和 Ispire 隨後向美國證券交易委員會提交的任何文件中所述的其他風險。 前瞻性陳述不應視作對未來事件的預測。 本新聞稿中所作的前瞻性陳述僅與本新聞稿發佈之日發生的事件或資訊有關。 除適用法律另有規定外,我們不承擔在聲明發佈之日後因新資訊、未來事件或其他原因而更新或修改任何前瞻性陳述的義務,也不承擔反映意外事件發生的義務。 閱讀本新聞稿時應理解,我們未來的實際業績可能與我方預期有重大差異。

    ISPIRE TECHNOLOGY INC.

    未經審核簡明綜合資產負債表

    (以美元計算,股份及每股數據除外) 




    2025 年 12 月 31 日



    2025 年 6 月 30 日


    資產







    流動資產:







    現金


    $

    17,565,334



    $

    24,351,765


    受限制現金



    50,000





    應收帳款淨額



    37,878,353




    39,664,145


    庫存



    5,037,414




    6,647,970


    預付費用及其他流動資產



    3,120,978




    2,244,505


    流動資產總額



    63,652,079




    72,908,385


    非流動資產:









    應收帳款,扣除流動部分






    7,367,158


    物業、廠房及設備淨額



    2,599,861




    2,952,800


    無形資產淨值



    2,474,037




    2,232,620


    使用權資產 – 經營租賃



    4,335,355




    5,030,005


    其他投資



    2,000,000




    2,000,000


    權益法投資



    9,129,213




    9,515,546


    其他非流動資產



    210,617




    210,617


    非流動資產總值



    20,749,083




    29,308,746


    總資產


    $

    84,401,162



    $

    102,217,131


    負債及股東權益









    流動負債









    應付帳款


    $

    3,137,235



    $

    4,172,476


    應付帳款 – 關聯方



    42,444,624




    52,420,256


    合約負債



    4,971,135




    4,861,250


    應計負債及其他應付款項



    6,818,397




    8,099,991


    應課税入息



    12,590





    借款 - 流動部分



    1,146,766




    1,146,766


    租賃負債-流動部分



    1,659,698




    1,838,815


    流動負債總額



    60,190,445




    72,539,554











    非流動負債:









    應付關聯方款項



    29,000,000




    25,000,000


    借款 – 扣除流動部分



    231,978




    805,361


    經營租賃負債-扣除流動部分



    2,642,156




    3,267,522


    非流動負債總額



    31,874,134




    29,072,883


    負債總額



    92,064,579




    101,612,437











    承付款項及或有負債


















    股東(赤字)/權益:









    普通股,每股面額 0.0001 美元;已授權發行 1.4 億股;
    截至 2025 年 12 月 31 日
    及 2025 年 6 月 30 日已發行及流通在外的股票分別為 57,289,864 股及 57,193,734 股。



    5,729




    5,719


    庫存股(按成本計)



    (105,489)




    (60,488)


    額外實收資本



    50,593,580




    48,833,601


    累積赤字



    (57,927,041)




    (48,065,267)


    累計其他綜合虧損



    (230,196)




    (108,871)


    股東(赤字)/權益總額:



    (7,663,417)




    604,694


    負債及股東(赤字)權益總額


    $

    84,401,162



    $

    102,217,131


    ISPIRE TECHNOLOGY INC.

    未經審核簡明綜合經營業績及
    綜合虧損表

    (以美元計算,股份及每股數據除外) 




    截至
    12 月 31 日止三個月



    截至
    12 月 31 日止六個月




    2025



    2024



    2025



    2024















    收益


    $

    20,286,556



    $

    41,827,860



    $

    50,637,440



    $

    81,166,173



















    營業成本



    16,811,955




    34,105,289




    42,016,067




    65,769,224



















    毛利



    3,474,601




    7,722,571




    8,621,373




    15,396,949



















    營運開支:

















    銷售及市場推廣費用



    1,476,328




    2,061,664




    3,041,172




    5,053,911


    信貸減值支出



    4,209,201




    4,183,998




    5,973,453




    7,286,079


    一般及行政開支



    4,663,939




    8,836,964




    9,176,924




    15,679,883



















    總營運開支



    10,349,468




    15,082,626




    18,191,549




    28,019,873



















    營運虧損



    (6,874,867)




    (7,360,055)




    (9,570,176)




    (12,622,924)



















    其他收入(開支):

















    利息收入



    104,922




    59,755




    200,394




    59,841


    利息支出



    (100,191)




    (13,073)




    (212,367)




    (24,537)


    匯兌收益(虧損)淨額



    290,237




    (245,173)




    300,039




    (127,588)


    其他收入淨額



    83,574




    19,934




    12,991




    38,333



















    其他收益(支出)淨總額



    378,542




    (178,557)




    301,057




    (53,951)



















    扣除入息稅前虧損



    (6,496,325)




    (7,538,612)




    (9,269,119)




    (12,676,875)



















    入息稅



    (106,586)




    (460,031)




    (592,655)




    (916,784)



















    淨虧損


    $

    (6,602,911)



    $

    (7,998,643)



    $

    (9,861,774)



    $

    (13,593,659)



















    其他綜合收益(虧損)

















    外幣報表折算差額



    (113,433)




    73,470




    (121,325)




    (81,467)


    綜合虧損


    $

    (6,716,344)



    $

    (7,925,173)



    $

    (9,983,099)



    $

    (13,675,126)



















    每股淨虧損

















    基本及攤薄


    $

    (0.12)



    $

    (0.14)



    $

    (0.17)



    $

    (0.24)



















    加權平均流通在外股數:

















    基本及攤薄



    57,258,218




    56,658,012




    57,257,938




    56,629,666


    如需更多資訊,請聯絡:

    投資者關係聯絡人:
    KCSA Strategic Communications
    Phil Carlson
    212-896-1233
    [email protected]

    公共關係聯絡人:
    Ellen Mellody
    570-209-2947
    [email protected]

    SOURCE Ispire Technology Inc.


    Read original release

  • Ispire Technology Inc.、2026年度第2四半期決算を発表

    Ispire Technology Inc.、2026年度第2四半期決算を発表

    継続的な回収に注力し、2025年6月30日以降、純売掛金を19%削減

    キャッシュ残高は 2025年12月31日時点で1760万ドル 

    ロサンゼルス, 2026年2月7日 /PRNewswire/ — 電子タバコ技術と精密投与の先駆者であるIspire Technology Inc. (NASDAQ:ISPR) (以下「Ispire」または「当社」)は本日、2026年度第2四半期(2025年12月31日を期末とする3カ月間)の決算を発表しました。

    2026年度第2四半期決算

    • 売上高は2030万ドル(対して2025年度第2四半期は4180万ドル)。
    • 売上総利益は350万ドル(対して2025年度第2四半期は770万ドル)。
    • 売上総利益率は17.1%(対して2025年度第2四半期は18.5%)。
    • 営業費用合計は1030万ドル(対して2025年度第2四半期は1510万ドル)。
    • 純損失は660万ドル(対して2025年度第2四半期の純損失は800万ドル)。

    Ispireの共同最高経営責任者であるMichael Wangは、「この四半期は、Ispireにとって1年にわたるコスト削減と顧客品質の合理化努力の変曲点でした。今後の数四半期には、トップラインの成長、安定したキャッシュフロー、ボトムラインの改善が見込まれます。さらに、将来の成功に向けた強固な基盤を築くことができたと確信しています。2026年度第2四半期は、質の高い売上高を優先し、持続可能な成長への規律ある意図的なアプローチを強化することに重点を置きました。このことは特に、純売掛金を削減する取り組みにおいて顕著であり、引き続き大きな成果を上げています。第2四半期には、純売掛金を2025年度末の4700万ドルから19.5%削減し、3790万ドルに押さえることができました」と語っています。

    続けてWangは、「2026年度中の増産に向けて、マレーシアにおける製造能力の増強など、事業の中核となる分野で重要な土台作りを継続しています。当社独自のG-Mesh技術に対する機運は引き続き高まっています。それに伴い、複数の大手・中堅ニコチンメーカーが次世代電子タバコ機器への採用を検討する協議を進めており、ライセンス供与や提携機会の可能性に向けて取り組んでいます。さらに、当社の合弁事業であるIKE Techは、ヨーロッパ、東南アジア、中東の規制当局と連携し、より安全な業界標準としての年齢確認(エイジゲーティング)技術の普及を支援するなど、着実にグローバルな進展を遂げています。  米国では、成人消費者の大半がフレーバー付き電子タバコを望みます。しかし、フレーバー付き電子タバコは、ほぼすべてFDAの認可を得ておらず、違法ルートで販売されています。  米国連邦政府が電子タバコ違法取引の取り締まりを強化することについては歓迎します。しかし、こうした取り締まりは、FDA認可のフレーバー付き電子タバコ製品の強固で合法的な市場の創出と組み合わせることで初めて、真に効果的になるのではないでしょうか。IKEを擁するIspireは、合法的で承認された製品の市場を創出する重要な役割を担っています。すなわち、若年層のアクセスを防止し、製品の真正性を確保し、不正使用発生前にデバイスを保護するソリューションを提供する技術を駆使することです。米国FDAがフレーバー付きENDS製品および年齢制限に関する立場を表明したことで、当社にとって今まさにマクロ的な追い風が吹いています。2025年10月以降、FDAは、フレーバー製品の認可を受ける場合には年齢制限技術の導入を必須とする、という立場を明確にしています。Ispireはというと、IKE合弁事業を通じて、この分野の先端であり最も低摩擦の技術を有しています。そのことから、いずれこのチャンスを生かせることを楽しみにしています」と締めくくりました。

    Ispireの最高財務責任者であるJay Yuは、「2026年度第2四半期は、財務基盤の強化に注力した結果、継続的な進展が見られました。厳格なコスト管理により、営業費用は前年同期比で減少しました。第2四半期には1510万ドルから1030万ドルに減少し、当社の効率化施策の成果を裏付けるものになっています。また当社の純売掛金は、2025年6月30日時点の4700万ドルに対して、2025年12月31日時点では3790万ドルへと減少しました。このことは、より質の高い顧客への継続的な取り組みを反映しています。こうした措置により、当社は財務の柔軟性を高め、長期にわたる持続的な価値創造を支援してきたのです」と述べています。

    2025年12月31日を期末とする第2四半期終了時点における決算

    Ispireにおける2025年12月31日を期末とする第2四半期の売上高は2030万ドルでした。これは、前年同期の4180万ドルより減少しています。こうした減収は低品質の大麻顧客からの戦略的撤退によるものであり、結果として製品全体の売上高は減少しました。 

    2026年度第2四半期の売上総利益については350万ドルでした。前年同期の770万ドルから減少しています。売上総利益率は17.1%であり、2025年度第2四半期の18.5%に比べて低くなっています。売上総利益率の減少は主に、2025年12月31日を期末とする3ヵ月間において利益率の高い製品の販売が減少したことによる製品構成の変化によるものです。

    2026年度第2四半期の営業費用総額は1030万ドルであり、前年同期の1510万ドルに比べて減少しています。

    2026年度第2四半期の純損失は660万ドル、すなわち1株当たり0.12ドルです。それに対して、2025年度第2四半期の純損失は800万ドル、すなわち1株当たり0.14ドルでした。

    2025年12月31日時点で、Ispireは1760万ドルの現金と350万ドルの運転資本を保有していることになります。

    カンファレンスコール

    当社は、2026年2月6日(金)午前8時(米国東部時間)よりカンファレンスコールを実施し、その後質疑応答を実施します。

    決算説明会をお聞きになるには、以下の情報を使用してお電話でご参加ください。電話接続時に案内があった際は、「Ispire Technology Call」とお申し出ください。

    • 日付: 2026年2月6日(金)
    • 時間: 米国東部時間午前8時
    • ダイヤルイン番号: 米国から877-451-6152、米国外から +1 201-389-0879

    この電話会議はウェブキャストでライブ配信され、関係者全員が以下からアクセスできます:https://viavid.webcasts.com/starthere.jsp?ei=1749224&tp_key=1ec45fe266

    通話開始の少なくとも15分前までにリンクにアクセスして登録の上、必要なオーディオ・ソフトウェアのダウンロードおよびインストールを行なってください。

    アーカイブ再生は、2026年2月20日(金)午後11時59分(米国東部時間)までご利用いただけます。内容を聞くには、1-844-512-2921または1-412-317-6671にダイヤルしてください。アーカイブ再生にアクセスするには、パスコード13758138を使用してください。

     Ispire Technology Inc.について
    Ispire は、ブランド電子タバコおよび大麻用ベイピング製品の研究開発、設計、商品化、販売、マーケティング、ならびに流通に従事しています。当社の事業子会社は、世界で400件を超える特許を所有またはライセンスしています。Ispire のブランド電子タバコ製品は「Aspire」の名称で販売されており、米国・中華人民共和国・ロシアを除く世界各国で、主にグローバルな流通ネットワークを通じて提供されています。当社はまた、世界中の電子タバコブランドや小売業者とのODM(受託設計製造)関係にも取り組んでいます。当社の大麻製品は、Ispireのブランド名で主にODMベースで他の大麻蒸気会社に販売されています。Ispireは、米国、ヨーロッパ、南アフリカで大麻ベイピングハードウェアを販売しており、最近ではカナダ、ラテンアメリカでマーケティング活動と顧客エンゲージメントを開始しました。詳細については www.ispiretechnology.com をご覧いただくか、InstagramLinkedInTwitterYouTube でIspireをフォローしてください。

    将来予想に関する記述
    本プレスリリースには、1933年証券法(改正後、以下「証券法」)第27A条、1934年証券取引法(改正後)第21E条、および1995年私募証券訴訟改革法(改正後)に基づく「セーフハーバー」規定により保護されることを意図した将来予想に関する記述が含まれています。将来予想に関する記述は、一定の仮定に基づき、当社の将来の計画、戦略、期待を述べたものであり、一般的には、「信じる」、「期待する」、「かもしれない」、「だろう」、「すべきである」、「であろう」、「できる」、「努める」、「意図する」、「計画する」、「目標」、「計画する」、「見積もる」、「予想する」、「戦略」、「将来」、「可能性が高い」などの将来予想に関する用語、またはその他の類似の用語を使用することで識別できますが、すべての将来予想に関する記述にこれらの識別語が含まれているわけではありません。本プレスリリースに記載された、当社の戦略、見通し、財務状況、事業運営、コスト、計画および目標に関する記述のうち、過去の事実に関するものを除くすべては、将来予想に関する記述です。当社の実際の業績および財務状況が将来予想に関する記述で示された内容と大きく異なる可能性のある重要な要因には、以下のものが含まれます。そのような将来予想に関する記述には、以下を含むがこれらに限定されない、リスクや不確実性が含まれます:当社が米国ENDS市場への再参入に成功するかどうか。当社が提出したPMTAの承認または却下。当社がアフリカ市場へのさらなる進出計画を成功させられるかどうか。Touch Point Worldwide Inc. d/b/a/ BerifyおよびChemular Inc.との合弁事業(以下「合弁事業」)がその目標を達成できるかどうか、あるいは現在検討されているとおり、異なる条件で、あるいはまったくその目標を達成できないかどうか。合弁事業が電子タバコ技術分野で革新を起こす能力、またはニコチンベイピングデバイス用の年齢制限または年齢確認技術を開発する能力。当社の売掛金を適時に回収する能力。当社の事業戦略。当社がIspire ONE™に販売する能力。Ispire ONE™がその目標を達成できるかどうか。顧客がIspire ONE™の期待される利益を得る能力および市場における製品の成功。Ispire ONE™の安全性の証明。また、「リスク要因」、「経営陣による財務状況および経営成績の分析」、「将来予想に関する記述に関する注意事項」に記載されているリスクと不確実性、および2025年6月30日を期末とする IspireのForm 10-K年次報告書、およびIspireがSECに提出するその後の提出書類に記載されている追加のリスク。将来予想に関する記述を将来の出来事に関する予測として信頼すべきではありません。本プレスリリースにおける将来予想に関する記述は、本リリースに記載された日付時点の出来事または情報のみに関連しています。当社は、適用法により求められる場合を除き、新たな情報、将来の出来事、またはその他の理由により、本プレスリリースに記載された日付以降に将来予想に関する記述を更新または修正する義務を一切負いません。本プレスリリースは、当社の将来の実際の業績が当社の予想と大きく異なる可能性があることを理解した上でお読みください。

    ISPIRE TECHNOLOGY INC.

    未監査の要約連結貸借対照表

    (単位:米ドル、ただし株式数および1株当たりデータを除く) 




    12月31日、
    2025年



    6月30日、
    2025年


    資産







    流動資産:







    現金


    $

    17,565,334



    $

    24,351,765


    使途制限付預金



    50,000





    売掛金(純額)



    37,878,353




    39,664,145


    棚卸資産



    5,037,414




    6,647,970


    前払費用およびその他の流動資産



    3,120,978




    2,244,505


    流動資産合計



    63,652,079




    72,908,385


    非流動資産:









    売掛金(1年以内に回収予定のものを除く)






    7,367,158


    有形固定資産(純額)



    2,599,861




    2,952,800


    無形資産(純額)



    2,474,037




    2,232,620


    使用権資産 – オペレーティング・リース



    4,335,355




    5,030,005


    その他の投資



    2,000,000




    2,000,000


    持分法による投資



    9,129,213




    9,515,546


    その他の非流動資産



    210,617




    210,617


    非流動資産合計



    20,749,083




    29,308,746


    総資産


    $

    84,401,162



    $

    102,217,131


    負債および株主資本









    流動負債









    買掛金


    $

    3,137,235



    $

    4,172,476


    買掛金(関連当事者)



    42,444,624




    52,420,256


    契約負債



    4,971,135




    4,861,250


    未払費用およびその他の未払金



    6,818,397




    8,099,991


    未払法人税等



    12,590





    借入金 – 1年以内返済予定分



    1,146,766




    1,146,766


    オペレーティング・リース債務 – 1年内返済予定分



    1,659,698




    1,838,815


    流動負債合計



    60,190,445




    72,539,554











    非流動負債:









    関連当事者に対する債務



    29,000,000




    25,000,000


    借入金 – 1年以内返済予定分控除後



    231,978




    805,361


    オペレーティング・リース債務 – 1年内返済予定分控除後



    2,642,156




    3,267,522


    非流動負債合計



    31,874,134




    29,072,883


    負債合計



    92,064,579




    101,612,437











    コミットメントおよび偶発債務


















    株主資本(赤字)/合計:









    普通株式、額面1株当たり0.0001ドル、授権株式数140,000,000株。
         57,289,864株および57,193,734株 (2025年12月 31日時点および
          2025年6月30日時点 の発行済株式数)



    5,729




    5,719


    自己株式



    (105,489)




    (60,488)


    資本剰余金



    50,593,580




    48,833,601


    累積赤字



    (57,927,041)




    (48,065,267)


    その他の包括損失累計額



    (230,196)




    (108,871)


    株主資本(赤字)/合計



    (7,663,417)




    604,694


    負債および株主資本(赤字)/合計


    $

    84,401,162



    $

    102,217,131


    ISPIRE TECHNOLOGY INC.

    未監査の要約連結損益計算書および
    包括損失計算書

    (単位:米ドル、株式数および1株当たりデータを除く)




    12月31日を期末とする 3 か



    12月31日を期末とする 6 か




    2025年



    2024年



    2025年



    2024年















    売上高


    $

    20,286,556



    $

    41,827,860



    $

    50,637,440



    $

    81,166,173



















    売上原価



    16,811,955




    34,105,289




    42,016,067




    65,769,224



















    売上総利益



    3,474,601




    7,722,571




    8,621,373




    15,396,949



















    営業費用:

















    営業及びマーケティング費用



    1,476,328




    2,061,664




    3,041,172




    5,053,911


    貸倒損失



    4,209,201




    4,183,998




    5,973,453




    7,286,079


    一般管理費



    4,663,939




    8,836,964




    9,176,924




    15,679,883



















    営業費用合計



    10,349,468




    15,082,626




    18,191,549




    28,019,873



















    営業損失



    (6,874,867)




    (7,360,055)




    (9,570,176)




    (12,622,924)



















    その他の収入(費用):

















    受取利息



    104,922




    59,755




    200,394




    59,841


    支払利息



    (100,191)




    (13,073)




    (212,367)




    (24,537)


    為替差損益(純額)



    290,237




    (245,173)




    300,039




    (127,588)


    その他の収入(純額)



    83,574




    19,934




    12,991




    38,333



















    その他の収入・費用(純額)



    378,542




    (178,557)




    301,057




    (53,951)



















    税引前損失



    (6,496,325)




    (7,538,612)




    (9,269,119)




    (12,676,875)



















    所得税



    (106,586)




    (460,031)




    (592,655)




    (916,784)



















    純損失


    $

    (6,602,911)



    $

    (7,998,643)



    $

    (9,861,774)



    $

    (13,593,659)



















    その他の包括利益(損失)

















    為替換算調整勘定



    (113,433)




    73,470




    (121,325)




    (81,467)


    包括損失


    $

    (6,716,344)



    $

    (7,925,173)



    $

    (9,983,099)



    $

    (13,675,126)



















    1株当たり純損失

















    基本および希薄化後


    $

    (0.12)



    $

    (0.14)



    $

    (0.17)



    $

    (0.24)



















    加重平均発行済株式数:

















    基本および希薄化後



    57,258,218




    56,658,012




    57,257,938




    56,629,666


    詳細については、以下にお問い合わせください。

    IRお問い合わせ先:
    KCSA戦略コミュニケーション
    Phil Carlson
    212-896-1233
    [email protected]

    PRお問い合わせ先:
    Ellen Mellody
    570-209-2947
    [email protected]

    ロゴ – https://mma.prnewswire.com/media/2771569/Ispire_Technology_Logo.jpg

    SOURCE Ispire Technology Inc.


    Read original release